Total Payments
$124,150
2020 Payments
$13.06
Companies
2
Transactions
5
Medicare Patients
2,674
Medicare Billing
$405,749
Payment Breakdown by Category
Research$124,125 (100.0%)
Food & Beverage$25.36 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $124,125 | 3 | 100.0% |
| Food and Beverage | $25.36 | 2 | 0.0% |
Payments by Type
Research
$124,125
3 transactions
General
$25.36
2 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Allergan, Inc. | $124,138 | 4 | $0 (2020) |
| Sunovion Pharmaceuticals Inc. | $12.30 | 1 | $0 (2018) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2020 | $13.06 | 1 | Allergan, Inc. ($13.06) |
| 2019 | $108,080 | 1 | Allergan Inc. ($108,080) |
| 2018 | $13,100 | 2 | Allergan Inc. ($13,088) |
| 2017 | $2,957 | 1 | Allergan Inc. ($2,957) |
All Payment Transactions
5 individual payment records from CMS Open Payments
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/15/2020 | Allergan, Inc. | UBRELVY (Drug) | Food and Beverage | In-kind items and services | $13.06 | General |
| Category: NEUROSCIENCE | ||||||
| 01/22/2019 | Allergan Inc. | — | — | Cash or cash equivalent | $108,080.00 | Research |
| Study: EVALUATION OF THE SAFETY AND PHARMACODYNAMIC EFFECT OF AGN-151607 BY MEASURING THE COMPOUND MUSCLE ACTION POTENTIAL CMAP OF THE EXTENSOR DIGITORUM BREVIS EDB MUSCLE FOLLOWING A SINGLE INJECTION IN HEALTHY SUBJECTS | ||||||
| 12/13/2018 | Allergan Inc. | — | — | Cash or cash equivalent | $13,088.00 | Research |
| Study: Evaluation of the Safety and Pharmacodynamic Effect of AGN-151607 by Measuring the Compound Muscle Action Potential CMAP of the Extensor Digitorum Brevis EDB Muscle Following a Single Injection in Healthy Subjects | ||||||
| 02/02/2018 | Sunovion Pharmaceuticals Inc. | APTIOM (Drug) | Food and Beverage | In-kind items and services | $12.30 | General |
| Category: CNS | ||||||
| 12/31/2017 | Allergan Inc. | — | — | Cash or cash equivalent | $2,957.06 | Research |
| Study: Evaluation of the Safety and Pharmacodynamic Effect of AGN-151607 by Measuring the Compound Muscle Action Potential CMAP of the Extensor Digitorum Brevis EDB Muscle Following a Single Injection in Healthy Subjects | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| EVALUATION OF THE SAFETY AND PHARMACODYNAMIC EFFECT OF AGN-151607 BY MEASURING THE COMPOUND MUSCLE ACTION POTENTIAL CMAP OF THE EXTENSOR DIGITORUM BREVIS EDB MUSCLE FOLLOWING A SINGLE INJECTION IN HEALTHY SUBJECTS | Allergan Inc. | $108,080 | 1 |
| Evaluation of the Safety and Pharmacodynamic Effect of AGN-151607 by Measuring the Compound Muscle Action Potential CMAP of the Extensor Digitorum Brevis EDB Muscle Following a Single Injection in Healthy Subjects | Allergan Inc. | $16,045 | 2 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 7 | 608 | 4,164 | $167,193 | $87,575 |
| 2022 | 7 | 669 | 5,836 | $202,890 | $107,659 |
| 2021 | 8 | 704 | 4,890 | $203,840 | $108,913 |
| 2020 | 7 | 693 | 6,169 | $217,038 | $101,602 |
Total Patients
2,674
Total Services
21,059
Medicare Billing
$405,749
Procedure Codes
29
All Medicare Procedures & Services
29 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 166 | 228 | $50,616 | $27,080 | 53.5% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 109 | 109 | $35,970 | $17,157 | 47.7% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 154 | 198 | $30,888 | $16,784 | 54.3% |
| J0585 | Injection, onabotulinumtoxina, 1 unit | Office | 2023 | 15 | 3,440 | $26,144 | $16,351 | 62.5% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 112 | 122 | $14,640 | $6,769 | 46.2% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 17 | 17 | $5,185 | $2,176 | 42.0% |
| G2212 | Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or | Office | 2023 | 35 | 50 | $3,750 | $1,259 | 33.6% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 188 | 263 | $58,386 | $32,513 | 55.7% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2022 | 154 | 154 | $50,820 | $24,646 | 48.5% |
| J0585 | Injection, onabotulinumtoxina, 1 unit | Office | 2022 | 17 | 5,035 | $38,266 | $23,307 | 60.9% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 161 | 213 | $33,228 | $17,405 | 52.4% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 101 | 111 | $13,320 | $5,989 | 45.0% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 19 | 19 | $5,795 | $2,750 | 47.4% |
| G2212 | Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or | Office | 2022 | 29 | 41 | $3,075 | $1,050 | 34.1% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Office | 2021 | 170 | 258 | $57,276 | $32,979 | 57.6% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 205 | 279 | $43,524 | $22,539 | 51.8% |
| 99205 | New patient outpatient visit, total time 60-74 minutes | Office | 2021 | 132 | 132 | $43,560 | $21,884 | 50.2% |
| J0585 | Injection, onabotulinumtoxina, 1 unit | Office | 2021 | 14 | 3,975 | $30,210 | $17,788 | 58.9% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 107 | 122 | $14,640 | $7,419 | 50.7% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2021 | 17 | 18 | $5,490 | $2,701 | 49.2% |
| G2212 | Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or | Office | 2021 | 47 | 92 | $6,900 | $2,427 | 35.2% |
| 95886 | Needle measurement and recording of electrical activity of muscles of arm or leg complete study | Office | 2021 | 12 | 14 | $2,240 | $1,176 | 52.5% |
| 99215 | Established patient office or other outpatient, visit typically 40 minutes | Office | 2020 | 172 | 263 | $58,386 | $25,724 | 44.1% |
| J0585 | Injection, onabotulinumtoxina, 1 unit | Office | 2020 | 15 | 5,305 | $40,318 | $24,605 | 61.0% |
| 99205 | New patient office or other outpatient visit, typically 60 minutes | Office | 2020 | 149 | 149 | $49,170 | $20,916 | 42.5% |
About Dr. Raymond Sloop, MD
Dr. Raymond Sloop, MD is a Neurology healthcare provider based in Yakima, Washington. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 09/14/2006. The National Provider Identifier (NPI) number assigned to this provider is 1548365521.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Raymond Sloop, MD has received a total of $124,150 in payments from pharmaceutical and medical device companies, with $13.06 received in 2020. These payments were reported across 5 transactions from 2 companies. The most common payment nature is "" ($124,125).
As a Medicare-enrolled provider, Sloop has provided services to 2,674 Medicare beneficiaries, totaling 21,059 services with total Medicare billing of $405,749. Data is available for 4 years (2020–2023), covering 29 distinct procedure/service records.
Ad
Practice Information
- Specialty Neurology
- Location Yakima, WA
- Active Since 09/14/2006
- Last Updated 09/13/2024
- Taxonomy Code 2084N0400X
- Entity Type Individual
- NPI Number 1548365521
Products in Payments
- UBRELVY (Drug) $13.06
- APTIOM (Drug) $12.30
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.